Climb Bio
Redmond
About Climb Bio
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. Eliem Therapeutics develops and commercializes potentially “best-in-class” drug candidates to treat neuronal excitability disorders. These conditions’such as chronic pain, depression, epilepsy, and anxiety’cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $291.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:ELYM
- Website: eliemtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/climb-bio-126349 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.